Tag Archive for: Susvimo

Yesterday the company announced that it will reintroduce Susvimo (ranibizumab injection) in the U.S., which will make the eye implant available again for the treatment of patients with neovascular age-related macular degeneration.

Roche is dropping its investigational AKT inhibitor ipatasertib, which was being assessed in a Phase III trial for castration-resistant prostate cancer, the company revealed Thursday in its 2022 full-year financial report.